Good morning, good afternoon, good evening, or whatever time it is at your location. My computer states it's 8:01 A.M. in Oslo, so let's start. I am Bertel Karlstedt, and I want to wish you all a warmly welcome to this Circa Group release and presentation of the quarterly results for Q2 2024. The next slide. The traditional disclaimers. There are the traditional disclaimers. I won't go through that. We can take the next slide. The agenda today is more or less the traditional one. I will make an introduction of the situation in general, followed by Philipp Morgenthaler, covering FC5 and ReSolute status and progress during Q2, followed by Alessandro, covering the market and product development during said time, and then still have Erik on finance before my closing of the presentation with the outlook before the questions and answers session, then let's take the next slide. The topics are the same that has been covered before because the key focus of the operations and the management and the Circa has been the same as reported already in previous quarters, and during the Q2, the focus has very much been on the funding and finding the solution for the funding situation. As you have seen, and as you have been able to take part of the releases during Q2 and also the release on July 21st, we now know that based upon price escalation, further delays in the project, as well as the decision to seek a funding solution covering the needs up until end of 2026, the company is now seeking a funding of altogether EUR 60 million. That is the state and the fact, and that is the, should I say, the most difficult topic we have in front of us. Looking at the business plan and what we see in the market, we actually have an interesting development, looking at market progress, market response, and that is the fact that there is an opening for a bigger focus and effort on our side for high-value applications that has a very positive impact on the business plan that we see in front of us for the coming five or six first years up until twenty thirty, that we have tried to envision, and that really supports the views on the Circa future with the Resolute units up and running. The third thing I want to bring forward is the fact that we have a strong French support on many fronts for the Resolute progress and materialization and finalization. One part of that is the fact that we also have an opportunity now, with certain preconditions, to achieve a loan-based funding and finance solution from France that will constitute part of the altogether EUR 60 million that we are needing. Progress on that front, this is an alternative to the loan opportunity we also have from the Finnish export credit, Finnvera, that has been communicated already some time ago. Both opportunities do exist side by side, and either one we would like to leverage and implement. Going further down to Resolute, Philipp will go more into details, but certain things I want to highlight briefly. And my part, for the first thing during Q2 and since our previous quarterly release and presentation, this work at the site has now stopped based upon the fact that we can't go any further without the environmental permit in our hand. The positive thing, looking at a longer-term perspective, is that we have been able to renegotiate the rent lease agreement with Gazelle Energie, our landlord at Saint-Avold, where we are building Resolute. We had a nine-year contract. We have now been able to extend that, and are in agreement with Gazelle Energie to extend that to 15 years, with an opportunity for us for further extension post the 15 years. Like I said, a very good long-term achievement, talking about the future of the company. The French support actually is on multiple dimensions and multiple fronts. I mentioned the financial support through the banks. We also have a very strong local support, regional support, but also a national level, you could say, political, administrative support. There is a ministry-appointed official called the DIAT, who is very strongly at our side, supporting us, opening doors, and paving the way for solutions for the issues we have, especially talking about both funding and the environmental permit. Strong support, really strong support, highly appreciated. And having said that, the close cooperation with the authorities, locally and regionally, for achieving the environmental permit is also very much ongoing, continuing, and right now, the view is that the environmental permit will be in our hand by the end of this year, during Q4. I will go further to the market. That will be covered, market applications and commercialization, more detail, again, by Alessandro. But... I want to state that there are multiple fronts active towards distributors and users, as well as, potential, contract manufacturers and contract manufacturing and research organizations that we would need, in our network to facilitate the high-value applications and the production and distribution of those. That is important. Important is also that, the company continues to be very visibly present in different type of industry events, in, customer events, and that will continue during the fall. Something that has happened during the summer was, as an example, Alessandro participated in the TransPharm Project event in Dublin, Ireland. As we know, pharma is an industry of big interest to us, and with lots of potential, and our presence and visibility in conjunction with that is important. And, I would state that to support the business plan, to be able to leverage the plans that... The views that we have, that we have identified related to the high-value applications, that is a key thing, and we have multiple opportunities there as well, and good progress. I know that Alessandro will share more light on that in his portion. With those words, covering funding related to the business plan implementation, the finalization of Resolute, as well as the present status of market application and commercialization, I would then leave the floor over to Philipp, that will give more information about the status, progress, and ongoing activities at both FC5 and Resolute. Philipp, the floor is yours. Thank you, Bertel. Good morning, and good afternoon, everyone. Please, next chart, Erik. Thank you. So update on FC5, we have been able to finish a few of the projects we have been working on, and we have been talking about in previous meetings. So the installation of the lab-scale LGO distillation facility has been completed now, so we are able to produce high-purity levoglucosan now to support development work. So the production of levoglucosan with a purity of greater than 99% has already been achieved. We're able to produce about three liters of that product now on a weekly basis, which I said, can support all further development activities for the new derivatives. We also have completed the implementation of a basic quality management system, according to ISO 9001. This system will also form the basis for a future implementation of quality management systems across also Resolute. With this quality management system, we have been able to close all the open topics from the pharmaceutical customer audit we had last December, so we are now officially qualified by a Chinese pharmaceutical customer, and knowing that the requirements of the Chinese pharmaceutical industry are tougher than the ones in the United States or in Europe, this is a great accomplishment and shows the level of systems we have implemented at FC5. We have also worked on the operational costs. We have done trials to reduce the sulfolane consumption, which is one of the major material costs we have. We have been able to reduce this cost by the consumption by 30%, which will have a significant impact on OPEX going on. Also, the operations in Tasmania have been put on hold, and the team has been reduced to a minimum required to keep the lab activities going and to maintain the plant. This was the update on FC5. Next chart, please, Erik. So at Resolute, as Bertel mentioned, we have a great support from the government, not only from the DIHAP, but also from the Prefecture. The DIHAP actually organized an event, a public event at the site in order to create awareness for Circa's activities and funding activities. We took the opportunity of the unloading of the distillation equipment, and in the middle picture you see, in the center, you see the prefect. On his left, you see the sub-prefect. On the far right, you see the President of CASAS, which is the local community organization. A great attendance. We had coverage of radio, TV stations, and newspapers. Also, going into Germany, the event created an interview with the Südwestrundfunk, which is actually the public broadcasting agency in all over Germany. So a lot of attention created, which hopefully is paying off. Next chart, please, Erik. On Resolute, the civil works at the quotation for the civil works is pending. We have an agreement with one of the subcontractors, and that they will complete their part of the work, which is the roads and the underground network. The rest of the quoting is going on. So, once we have the permit, we will be able to continue works immediately. The mechanical erection and piping works have not been awarded yet. Discussions with vendors are paused. As Bertel mentioned, the lease extension with Gazelle, which is a great achievement. On the equipment side, we have the majority of the equipment is there. 95% of the equipment from the major packages, pyrolysis, boiler, pyrolyzer, and distillation are at the site. Wood yard and hydrogenation equipment is fully built and stored at locations close to the vendors, ready to be dispatched and received at Saint-Avold. Balance of plant items are partially completed and delivered. Smaller packages are yet to be awarded, and with that, with those then the engineering can be completed. On the permitting side, we have received the comments from the Mission Régionale d’Autorité Environnementale. So we have two agencies. We have DREAL, who in the end will grant the permit or will make a recommendation to the prefect to grant the permit. But we have this Mission Régionale d’Autorité Environnementale, which is actually reviewing the file. We have received their comments on the eighteenth of July and have answered all their questions. In order to show his support, the prefect invited all relevant stakeholders, including ourselves, to a meeting on the seventh of August, and he reiterated his commitment to contribute to signing of the permit in October. He made it clear to all, the participants of the meeting that this time plan must be kept, and he was making pressure on his departments in order for us to get this permit. As a result of that, the commissioner for the public inquiry has been nominated, and he visited us last week at the site. He also clearly signaled his support, will do everything he can to actually support the time plan. The public inquiry will now start on the 26th of August and go for one month until the 24th of September. Then, we have to go through a few formalities, final report of the commissioner, final report of DREAL, and then these documents, they will go into a CODERST. The CODERST is the Conseil Départemental de l'Environnement et des Risques Sanitaires et Technologiques, so the environmental conciliator and the sanitary risk meeting has to take place. And once the CODERST gives green light, the prefect will sign the permit immediately as he has it on his desk, and we expect that still by mid of October to happen. So progress on permitting now going into the final stage of the public inquiry next Monday. And with that, I would like to hand over to Alessandro for an update on market and R&D. Thank you for your attention. Thank you, Philipp. Good morning, good afternoon, everyone, and I would like to start the part the presentation on the market and product development activities with the highlights in Q2 2024. We see a continuous demand in and requests for pricing of Cyrene, and we are engaging in sampling activities with direct customers. So this is confirming the interest from the market in Circa's products. As mentioned by Bertel and also by Philipp, we are increasing the attention and the activities in the space of pharmaceutical applications. And so we are setting the stage for a number of partnerships to develop what we call the intermediate business, which means all the products that are derived from the LGO or from the Cyrene molecules. We're also engaging with global players, especially in the cosmetics or fragrance and flavors space. So we are moving into collaborations to develop further this part of the product line for Circa, which is the derivatives or whatever is modified from LGO. As well, we're exploring partnerships in solutions in carbon capture and storage, so materials that can be renewable, but can also function as carbon capture systems in large industrial installations. At the same time, we still have activities in what we consider more the, you know, the larger market, which is in solvents, which is, for example, the coating part. And again, I will stress in the next slides the importance as well, how we propose our solution to the customers. In terms of distribution, I think again, we see orders from EU-based and American-based distributors, which is suggesting that there is continued development at their customers. We are also, to be able to develop the intermediate, we are engaging with contract manufacturing organizations to be able to scale up what we think is the process to modify LGO. And at the same time, we are also signing agreements to develop the business of solvent, but focusing on solvent plants. This is something that we see potential for Circa, and for Cyrene to enter into customers' applications. The outlook for the next quarter is definitely we shall see, and we will see results from the recently signed agreements. Definitely, we already see, as announced in the previous quarter, the collaboration with the distributor based in Australia, that we see engagement and interaction with customers. So that's very extremely important. And we gonna finalize some of the other agreements on LGO derivatives that we are, that are currently under negotiation. and we should expect, as well, we will expect some results of the process development activities with the contract manufacturing organization on the intermediates. If we go to the next slide, and I'm going to try to explain as well the increased attention on the pharma or the specialty chemicals market. I would like to spend one slide on this, because this is basically has been mentioned already earlier, and we are putting an increased effort in this space. So we know that the intermediate market in general, especially the pharma intermediate market, is even larger than the solvent market. The fragrance and flavors chemicals market that showed difficult, which for the chemicals industry showed the resilience. And this means that this also, those are markets that are growing and are very solid and are less dependent on economic downturns. At the same time, those applications in this area are much more open to innovation, so are less price sensitive, and therefore, we see great opportunity for innovation and for positioning our products. The fact that we are offering not only chemicals from renewable sources that are potentially less toxic than existing solutions, but also new, completely new, and this is an added value that we are stressing with our potential customers. Now, how do we get there? I mentioned already, partnerships are extremely important. We're not in the position to develop everything by ourselves, and we need to work together with customers to develop specific intermediates. The process development and being able to upscale those products is extremely important, and that's why we need to collaborate with contract manufacturing organizations. We have active projects like TransPharm, which is active until 2026. It's a European-funded project addressing the generation of building blocks or pharmaceutical ingredients out from renewable sources, and this is an important project that is allowing us to explore different routes for developing those intermediates. Very important as well, while we are interacting with customers, we need to select which are the applications, the markets, the customers that are accessible to us and focus on them without dispersing energy on maybe markets and applications that are not targetable by Circa. I would like as well in the next slide now to give a general overview on how we're developing a sustainable and profitable product pipeline. The element of volumes, how we know that we will have a capacity up to one thousand two hundred tons. That's coming with Resolute, and we know that for a number of applications that we have targeted, we have the potential to reach those volumes, especially expanding the applications to consumer products, which are supported by the favorable outcome of the tox studies that are currently ongoing or being finalized. At the same time, we need to increase the distribution partnerships in other regions outside Europe, in the Americas and in the APAC region. Always continues to evaluate, and we are evaluating the distribution of partnerships in Europe, to make sure that we can accelerate the promotion of our product and also the qualification activities with customers. Any other additional opportunity that we have on funding, European funding or funding for projects that are on a later stage, means that are more advanced and are important for the market development, we will capture those opportunities. Now, how do we get to, being able to increase the average selling prices of Circa's products? As I mentioned earlier, solvent blends, are able to offer a competitive solution, increased performance to customers, and therefore, this is something that we are targeting at the moment. Making sure that the customers have a solution that can match their performance requirements and cost requirements as well. Also, activities ongoing to adapt to the solvent grade. This means that we're able to offer a solvent grade and to match requirements and performance at certain customers, but we're also able to offer higher grades for other applications. The development of the intermediates part of the business is also ongoing in partnerships. And this is also, we are able then to establish the value proposition together with the customer and also to reinforce any business case because we have the support and the interaction with the potential customers. The scale up is extremely important and to know the cost to manufacture, so that's why all the work we're doing with contract manufacturing organizations are so important. I let the stage to Erik. Thank you for your attention. Good morning, good afternoon, good evening. I will dive right into the numbers. The good thing is that a lot of progress has been made, both on the Resolute and last but not least, the sales and marketing. However, we are still without substantial revenues. The little revenue we have is basically grants being offset against operational expenses, and we are continuing to receive a lot of equipment, and also engineering through the Q2, which is well reflected in the half-year accounts that were published this morning. We have during the Q2 and well into the Q3 done our utmost to reduce cost spending, the so-called burn rate. However, a lot of equipment has been ordered a long time ago, and we're seeing deliveries of that through the summer and into the fall. The balance sheet is good and healthy. There is a good equity to assets ratio. However, it is going down as we are spending money on equipment and engineering. As even though that we've taken that down to a minimum level at this time, also has to do with the fact that we wouldn't be able to do much except storing equipment at Resolute without the mentioned permits. So in other words, most of the summer has gone through, and most of the quarter, or the end of the quarter went into managing cash and taking down costs so that we can keep on operating diligently and healthy. The largest project is, of course, the Project Resolute. There was an unpleasant surprise in finding that the project cost was very much higher than what we had anticipated. However, with the good efforts of the sales and marketing and the new product mix, we're seeing that the Resolute plant should become financially viable with healthy economics numbers. Even though the plant is built for 1,200 tons a year, the sales and operational numbers, including EBITDA, is based on approximately two-thirds of that capacity. So there is a surplus capacity that could also yield extra revenues and depending on the product mix, strengthen or weaken the EBITDA, but it should stay healthy as well. That's basically what I wanted to highlight. Cash management, cash management, and cash management is really what is occupying me together with the activities, fundraising and keeping the French authorities helpful. Okay. Thank you, Philipp, Alessandro, and Erik. Those presentations, those details and facts, kind of sets the scene for the outlook portion that I will cover as the last portion tomorrow - this morning. The topics that I will cover are the same that we have been covering during the last quarters: business plan and funding, Resolute and markets. On the funding side, should I go about it this way? The business plan is a function of the funding. The funding needs to find its solution, and we actually are looking into all options that are out there. The options are perhaps slightly increased by the fact that we have good EGM resolutions from the recent EGM meeting to support us. But, like we say, all options are looked into, including potential option of selling assets as well. As Erik brought forward, the cash situation is stretched, awaiting the funding solution to come about. That also means that we, as a company, we need to act really diligently toward all our operating stakeholders, and that is something that we need to do in this situation that will continue, that has been ongoing through the summer already, and that needs to continue throughout the fall and up until this funding solution is in its place. From a business plan perspective, a good, I could call it symbiosis between our internal work on high-value applications and what we see in the market, the interest, the progress, and the eagerness to develop jointly with us, that Alessandro brought forward, is the foundation for the revised business plan that Erik showed on his last slide. The view on the profitability of Resolute, and as a consequence of that, the foundation for Circa being a healthy company going forward with Resolute up and running, so focus on funding while awaiting the funding to come into place, securing operations diligently, and taking development further towards the business plan that we have created. Now, Philipp brought forward the details on Resolute, and in the case of Resolute, as we have heard, it's all about securing the environmental permit by the end of the year and securing a funding solution prior to that, and then we can continue the implementation and the finalization of Resolute. The readiness is there, and the aim is still to have the unit up and running by the end of 2025. Finally, Alessandro shared details on the market. I stress the need to come to a situation that we would have offtake agreements. That would open up so much the discussions with funding, but we also know that offtakes are difficult to get at this stage of the company development, with the unit still not operational and the volumes still not out there, but the efforts will continue to lengthen the list of distribution agreements that we have secured, and hopefully also get an offtake agreement, or a few of them, as soon as possible. And to support that, to support the business plan, the continued effort, internal and externally, on the high-value products will continue. This is the outlook: funding, supporting the business plan. The business plan needs the Resolute unit and the market commitment, and the continued traction and efforts in the marketing phase and place. With those words, I would thank you all for your participation and, and that you have listened in, and now we come to the questions and answers session. Any questions by anybody online, or I guess there is a chat opportunity as well, but let's check. Any questions, anybody, please? Anything in the chat either? Not that I can see. Okay. If, if there are no questions, there will be no answers as either. One more time, I appreciate, I thank you for your participation, your interest, and we look forward to your interest and support in the future as well. With those words, thank you one more time to Philipp, Alessandro, and Erik for your contribution. Thank you to everybody who made this situation, this event and the material available for us. Thank you all. Have a good continuation of the day.